Company news

NeuroSense Therapeutics Ltd. news in 2022

NeuroSense Therapeutics Ltd.'s news releases, calls and decks from 2022, newest first.

View company

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

November 30, 2022

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

November 15, 2022

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

November 14, 2022

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

October 26, 2022

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

October 20, 2022

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

September 27, 2022

NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial

September 19, 2022

NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

September 18, 2022

NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update

August 30, 2022

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

August 1, 2022

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study

June 29, 2022

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

May 31, 2022

NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

May 30, 2022

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

April 10, 2022

NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC

April 5, 2022

NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises

March 24, 2022

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS

March 20, 2022

NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences

January 3, 2022

Decks in 2022